EFFECTS OF D1 AND D2 AGONISTS ON SPONTANEOUS MOTOR-ACTIVITY IN MPTP TREATED MICE

被引:13
作者
FREDRIKSSON, A
PLAZNIK, A
SUNDSTROM, E
ARCHER, T
机构
[1] UNIV GOTHENBURG,DEPT PSYCHOL,S-40020 GOTHENBURG,SWEDEN
[2] UNIV UPPSALA,DEPT TOXICOL,S-75123 UPPSALA,SWEDEN
[3] INST PSYCHIAT & NEUROL,PL-02957 WARSAW,POLAND
[4] KAROLINSKA INST,S-14101 STOCKHOLM,SWEDEN
来源
PHARMACOLOGY & TOXICOLOGY | 1994年 / 75卷 / 01期
关键词
D O I
10.1111/j.1600-0773.1994.tb00321.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Two experiments were performed to study the effect of combining bromocriptine with SKF 38393 (SKF), or vice/versa, upon parameters of spontaneous motor activity in MPTP treated and saline (control) treated mice. Treatment with MPTP (2 x 40 mg/kg, subcutaneously) induced a hypoactive condition compared with saline treated mice. Bromocriptine (10 mg/kg, subcutaneously), administered to MPTP mice 2 hr, but not 1 or 4 hr, after SKF (6 mg/kg, subcutaneously) caused a marked increase in locomotion and rearing behaviour. The administration of bromocriptine (10 mg/kg, subcutaneously) 4 hr before SKF (6 mg/kg, subcutaneously) elevated all three parameters of spontaneous activity-in the MPTP treated mice, independent of the injection of SKF Bromocriptine injection 1 or 2 hr before SKF decreased locomotion in both MPTP and control mice. Neurochemical analysis confirmed the dopamine depletion in the MPTP treated mice. These results are discussed in terms of the reliability of the MPTP model of parkinsonism in mice and the dopamine D1/D2 receptor hypersensitivity following denervation with the neurotoxin.
引用
收藏
页码:36 / 41
页数:6
相关论文
共 42 条
[1]   CENTRAL NORADRENALINE DEPLETION ANTAGONIZES ASPECTS OF D-AMPHETAMINE-INDUCED HYPERACTIVITY IN THE RAT [J].
ARCHER, T ;
FREDRIKSSON, A ;
JONSSON, G ;
LEWANDER, T ;
MOHAMMED, AK ;
ROSS, SB ;
SODERBERG, U .
PSYCHOPHARMACOLOGY, 1986, 88 (02) :141-146
[2]   DOPAMINE D-1 RECEPTOR AGONISTS COMBINED WITH THE SELECTIVE D-2 AGONIST QUINPIROLE FACILITATE THE EXPRESSION OF ORAL STEREOTYPED BEHAVIOR IN RATS [J].
ARNT, J ;
HYTTEL, J ;
PERREGAARD, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1987, 133 (02) :137-145
[6]   PERMANENT HUMAN PARKINSONISM DUE TO 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP) - 7 CASES [J].
BALLARD, PA ;
TETRUD, JW ;
LANGSTON, JW .
NEUROLOGY, 1985, 35 (07) :949-956
[7]   A PRIMATE MODEL OF PARKINSONISM - SELECTIVE DESTRUCTION OF DOPAMINERGIC-NEURONS IN THE PARS COMPACTA OF THE SUBSTANTIA NIGRA BY N-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE [J].
BURNS, RS ;
CHIUEH, CC ;
MARKEY, SP ;
EBERT, MH ;
JACOBOWITZ, DM ;
KOPIN, IJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (14) :4546-4550
[8]   AROMATIC AMINO ACIDS AND MODIFICATION OF PARKINSONISM [J].
COTZIAS, GC ;
VANWOERT, MH ;
SCHIFFER, LM .
NEW ENGLAND JOURNAL OF MEDICINE, 1967, 276 (07) :374-&
[9]  
DUNCAN GE, 1987, J PHARMACOL EXP THER, V243, P1027
[10]  
DUVOISIN RC, 1986, RECENT DEV PARKINSON, P147